Part B Payment Model Indexing Commercial Discounts Proposed By Genentech
Executive Summary
Approach offered as alternative to more disruptive changes to Part B's existing buy-and-bill system; more aggressive proposals include new iteration of competitive acquisition program and moving Part B drug coverage to Part D.
You may also be interested in...
Cancer Drug Combination Pricing: Genentech Offers Model For Tecentriq, Avastin
Unique NDCs, Medicare reimbursement codes would allow for lower list prices for the drugs when used in combination for lung cancer, Genentech says.
Drug Pricing Reform In Medicare And Medicaid: Upcoming Regulatory Actions
Two highly anticipated proposed rules in Medicare Part D are scheduled for near-term release.
Medicare Value-Based Contracting, Vendor Price Negotiation To Be Tested In Part B Demo
CMS using authority from previously abandoned competitive acquisition program; vendors may get ability to use formularies and apply utilization management techniques like prior authorization and step therapy.